Author:
Oudard Stéphane,Timsit Marc-Olivier,Maillet Denis,Mouillet Guillaume,Campedel Luca,Colomba Émeline,Dourthe Louis Marie,Eymard Jean-Christophe,Gobert Aurélien,Jamet Claire,Joly Charlotte,Serrate Camille,Ploussard Guillaume
Reference58 articles.
1. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, et al. Global Cancer Observatory: Cancer Today (version 1.1). Lyon, France: International Agency for Research on Cancer. n.d. https://gco.iarc.fr/today/. (accessed April 10, 2024).
2. French AFU Cancer Committee Guidelines – update 2022–2024: prostate cancer – management of metastatic disease and castration resistance;Ploussard;Prog Urol,2022
3. Five-year survival prediction and safety outcomes with enzalutamide in men with chemotherapy-naïve metastatic castration-resistant prostate cancer from the PREVAIL trial;Armstrong;Eur Urol,2020
4. Real-world treatment patterns and overall survival of patients with metastatic castration-resistant prostate cancer in the US prior to PARP inhibitors;Shore;Adv Ther,2021
5. Overall survival among chemotherapy-naive patients with castration-resistant prostate cancer under abiraterone versus enzalutamide: a direct comparison based on a 2014–2018 French population study (the SPEAR cohort);Scailteux;Am J Epidemiol,2021